The Pharmagellan Guide to Biotech Forecasting and Valuation
Versandkostenfrei!
Versandfertig in 1-2 Wochen
93,99 €
inkl. MwSt.
PAYBACK Punkte
47 °P sammeln!
If you're a biotech executive, investor, deal maker, entrepreneur, or adviser—or aspire to be one—then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs. THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies. • Vetted benchmarks for key drivers of income, expenses, and valuation. • Proprietary analyses by Pharmagellan's experienced consulting team. • More than 150 current references from peer-re...
If you're a biotech executive, investor, deal maker, entrepreneur, or adviser—or aspire to be one—then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs. THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies. • Vetted benchmarks for key drivers of income, expenses, and valuation. • Proprietary analyses by Pharmagellan's experienced consulting team. • More than 150 current references from peer-reviewed research, industry white papers, and SEC filings. Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.
Andere Kunden interessierten sich für
